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Loss-of-function uORF mutations in 
human malignancies
Julia Schulz1, Nancy Mah2, Martin Neuenschwander3, Tabea Kischka4, Richard Ratei5,7, Peter 
M. Schlag6, Esmeralda Castaños-Vélez6, Iduna Fichtner1, Per-Ulf Tunn7, Carsten Denkert8, 
Oliver Klaas9, Wolfgang E. Berdel9, Jens P. von Kries3, Wojciech Makalowski4, Miguel A. 
Andrade-Navarro10, Achim Leutz  1,11 & Klaus Wethmar1,9
Ribosome profiling revealed widespread translational activity at upstream open reading frames (uORFs) 
and validated uORF-mediated translational control as a commonly repressive mechanism of gene 
expression. Translational activation of proto-oncogenes through loss-of-uORF mutations has been 
demonstrated, yet a systematic search for cancer-associated genetic alterations in uORFs is lacking. 
Here, we applied a PCR-based, multiplex identifier-tagged deep sequencing approach to screen 404 
uORF translation initiation sites of 83 human tyrosine kinases and 49 other proto-oncogenes in 308 
human malignancies. We identified loss-of-function uORF mutations in EPHB1 in two samples derived 
from breast and colon cancer, and in MAP2K6 in a sample of colon adenocarcinoma. Both mutations 
were associated with enhanced translation, suggesting that loss-of-uORF-mediated translational 
induction of the downstream main protein coding sequence may have contributed to carcinogenesis. 
Computational analysis of whole exome sequencing datasets of 464 colon adenocarcinomas 
subsequently revealed another 53 non-recurrent somatic mutations functionally deleting 22 uORF 
initiation and 31 uORF termination codons, respectively. These data provide evidence for somatic 
mutations affecting uORF initiation and termination codons in human cancer. The insufficient 
coverage of uORF regions in current whole exome sequencing datasets demands for future genome-
wide analyses to ultimately define the contribution of uORF-mediated translational deregulation in 
oncogenesis.
Ribosome profiling and numerous observations on individual transcripts characterized upstream open reading 
frames (uORFs) as repressive cis-regulatory elements, constitutively reducing translation rates of downstream 
main protein coding sequences (CDSs)1–4. A uORF is defined by a translational initiation codon preceding the 
CDS and a subsequent in-frame termination codon (uStop). Approximately 55% of human transcript leader 
sequences (TLSs) contain one or more AUG-initiated uORFs, which may precede or overlap the CDS initia-
tion site5. During canonical cap-dependent translation, ribosomes frequently initiate at upstream AUG (uAUG) 
codons, resulting in reduced translation of the associated downstream CDS3,6. Accordingly, uORFs regulate trans-
lation rates at the CDS by various mechanisms, including consumption of ribosomal pre-initiation complexes, 
induction of ribosome stalling at uStop codons, and nonsense-mediated mRNA decay7.
The regulatory impact of individual uORFs is highly dependent on transcript-specific features, including the 
position of the uORF within the TLS, its length and the quality of the uAUG-surrounding Kozak consensus 
sequence (uKozak). The uKozak sequence is optimal for ribosomal initiation in the context of GCCGCCAUGR 
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(with core Kozak bases underlined and R representing a purine base)8. Protein synthesis from uORF-bearing 
transcripts requires ribosomes to bypass the uORF initiation codon by leaky scanning or to re-initiate translation 
after termination at a uStop codon. Despite a mostly repressive effect on downstream translation, specific uORFs 
mediate a variety of molecular responses, including the translational induction of key regulatory proteins during 
the integrated stress response9,10, the adjustment of protein levels in response to uORF-specific co-regulators11, 
and the control of balanced protein isoform expression from a single transcript12.
Defective uORF-mediated translational control alters physiological processes across species from yeast9 to 
mice13. Furthermore, several human diseases result from the translational induction of proteins through a muta-
tional loss of uORF initiation codons, as exemplified by Marie Unna hereditary hypotrichosis14 and hereditary 
thrombocytosis15. To date, two mutations that enhance uORF-mediated repression in tumor suppressor genes 
have been linked to the development of human cancer. A point mutation found in hereditary melanoma intro-
duces a uORF in the CDKN2A gene resulting in decreased translation of the encoded CDK4/CDK6 kinase inhib-
itor16. Similarly, a 4-bp deletion within a uORF in the tumor suppressor gene CDKN1B caused lengthening of 
the uORF and enhanced repression of the cyclin-dependent kinase inhibitor p27KIP1 in a patient with multiple 
endocrine neoplasia syndrome type IV17. Despite such indications for a potential role of uORF mutations in tum-
origenesis, no comprehensive search for cancer-related uORF mutations has been performed.
We recently observed constitutive uORF-mediated translational repression of a number of human tyrosine 
kinases and other proto-oncoproteins, hinting at a mechanism of enhanced proto-oncogene expression through 
loss-of-function uORF mutations in cancer development5. Here, we developed a screening approach combining 
PCR amplification and deep sequencing to simultaneously investigate selected uORF start site regions in various 
cancer samples of different entities. We screened 308 human malignancies for loss-of-uAUG mutations in 404 
uORF initiation sites of 132 potential proto-oncogenes. Additionally, we analyzed 464 whole exome sequencing 
datasets of colon cancer for mutations in uORF-related initiation and termination codons. Our data revealed a 
number of non-recurrent loss-of-uAUG, loss-of-uStop and uKozak-affecting mutations in various types of cancer 
and suggest that genetic defects in uORF-mediated translational regulation may contribute to malignant trans-
formation in vivo.
Results and Discussion
A PCR-based, multiplex identifier-tagged deep sequencing approach for the identification 
of uORF mutations. To systematically search for genetic alterations affecting uORF initiation codons 
(uAUGs) and related Kozak consensus sequences (uKozaks), a PCR-based, multiplex identifier (MID)-tagged 
deep sequencing approach was established (Fig. 1). We included 308 hematologic and solid tissue malignancies, 
comprising samples derived from acute myeloid leukemia (AML, 50 cases), acute lymphoblastic leukemia (ALL, 
50), non-Hodgkin lymphoma (NHL, 50), osteosarcoma (OS, 35), mammary carcinoma (MC, 20), lung (LA, 
25) and colon (CA, 29) adenocarcinoma, and a number of mouse xenografts of human colon tumors (CX, 26) 
and lung adenocarcinoma (LX, 23) (Fig. 1A). Pre-test histological or cytological analysis confirmed a tumor cell 
content ≥50% for each sample. To define the uORF-target set, we mapped genomic positions of all uORF ini-
tiation codons in 132 cancer-associated genes (Fig. 1B, Supplementary Table 1), comprising 83 human tyrosine 
kinases (TKs)5, 46 validated proto-oncogenes overexpressed or amplified in human cancer18, and three candidate 
genes post-transcriptionally induced in cancer cell lines19. Target regions were amplified from cancer-derived 
DNA in a first round of PCR using uAUG-specific oligonucleotides containing a 5′-universal linker sequence 
(Fig. 1C). After quantitative normalization, all uAUG-specific amplicons of the same cancer sample were pooled 
and subjected to a second round of PCR adding a MID sequence tag via the previously attached universal linker 
sequence. Finally, MID-tagged cancer-specific pools were again normalized for DNA content, combined, and 
used to generate a single multiplex library for deep sequencing. As a whole, the screening protocol enabled the 
simultaneous investigation of 404 uORF translational start sites in 308 human cancer samples, equaling 124,432 
individual genomic regions.
Identification of uORF-associated genetic alterations in human malignancies. Approximately 
120 million sequencing reads with sample-specific MID-tags were generated and could be assigned unequivocally 
to individual cancers. All reads were computationally aligned to the human reference genome (hg19), resulting in 
recovery of all, except two, of the expected uAUG-specific amplicons. The median target-specific read coverage 
of 103 was lower as compared to the expected average of approximately 1000 reads per target region and showed 
high variation in site-specific read counts (0 to 160,060 reads per site). Despite thorough quantitative adjust-
ments after the first and second round of amplification, 45% of total sequencing reads mapped to the top 5% of 
covered target sites (Supplementary Table 2). Across cancer samples the distribution of reads per amplicon was 
similar (Fig. 2A, Supplementary Table 2), suggesting that site-specific efficiencies of individual PCRs accounted 
for the variance in read coverage, rather than differences in DNA quality. After all 80.2% of the 124,432 individual 
genomic regions were covered by 10 or more sequencing reads (Fig. 2A,B, top) and qualified for further analysis.
Nucleotide positions with more than 10% deviation from the reference genome were classified as potential uORF 
variant calls, as a heterozygous mutation in a sample containing 50% malignant cells would result in a 25% deviation 
of reads and cancer samples may be genetically diverse. Applying these filters, sequence alignments identified 45 
candidate mutations affecting uAUGs and 139 candidate mutations affecting uKozak sequences (Fig. 2B, bottom; 
Supplementary Tables 3 and 4). Additionally, 6 and 21 annotated uORF-associated single nucleotide polymorphisms 
(SNPs) as well as long deletion/repeat regions20 were detected in uAUG codons and uKozak sequences, respectively. 
Selected Sanger re-sequencing of independently generated uAUG-specific amplicons validated the presence of three 
out of three uAUG-deleting SNPs and eight out of nine uKozak SNPs (Table 1, Supplementary Tables 3 and 4), 
demonstrating the suitability of our approach to identify genetic variants at single nucleotide resolution.
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We then selected 33 uAUG and 23 uKozak candidate mutant sites for validation by Sanger re-sequencing 
after manual exclusion of cases, where low read numbers and variable nucleotide substitutions within the same 
sample indicated probable false positive mutation calls (Fig. 2B, Supplementary Tables 3 and 4). Finally, Sanger 
re-sequencing confirmed five novel uORF-associated mutations in individual cancer samples, resulting in the loss 
of a uORF initiation codon in four cases and in the alteration of the uKozak sequence in one individual (Table 2, 
Supplementary Tables 3 and 4). The distribution of sequencing reads indicated heterozygous loss-of-uAUG muta-
tions in various cancers, affecting the Src family tyrosine kinase BLK proto-oncogene (BLK) in a colon adeno-
carcinoma, the ephrin receptor B1 (EPHB1) in a mammary carcinoma and a colon cancer xenograft, the Janus 
kinase 2 (JAK2) in a sample of chronic lymphocytic leukemia, and the mitogen-activated protein kinase kinase 6 
Figure 1. Target sets and workflow of the PCR-based, multiplex identifier-tagged deep sequencing approach. 
(A) Composition of the cancer sample set with numbers indicating sample sizes of investigated malignant 
entities: ALL – acute lymphoblastic leukemia, AML – acute myeloid leukemia, NHL – non-Hodgkin lymphoma, 
OS – osteosarcoma, CA – colon adenocarcinoma, CX – colon xenograft, LA – lung adenocarcinoma, LX – lung 
xenograft, MC – mammary carcinoma. (B) Composition of the target gene set consisting of indicated numbers 
of uORF-bearing tyrosine kinases5, previously validated proto-oncogenes18 and genes post-transcriptionally 
induced in cancer cell lines19 (see also Supplementary Table 1). (C) Flow chart displaying amplification and 
normalization steps allowing simultaneous deep sequencing of 404 uORF initiation sites of 132 target genes in 
308 individual cancer samples. Briefly, genomic regions of uAUG targets were amplified individually from every 
cancer DNA (see also Supplementary Table 7). uAUG-specific amplicons of each cancer sample were pooled 
and labeled with cancer-specific MID-tags in a second round of PCR (see also Supplementary Table 8). After 
normalization and pooling of all MID-tagged amplicons, a deep sequencing library was generated and analyzed 
using the Illumina® HiSeq2000 sequencing system.
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(MAP2K6) in a colon adenocarcinoma. Additionally, the uKozak mutation affected the chromodomain helicase 
DNA binding protein 1-like gene (CHD1L) in a colon cancer xenograft. The somatic origin of uORF-related 
mutations was confirmed for the BLK and the CHD1L mutants, while the mutation observed in MAP2K6 was 
found to be a germline variant by analyzing normal tissue controls of affected patients (Supplementary Table 5). 
The mutations observed in EPHB1 and JAK2 could not be further characterized due to the lack of normal tissue.
Loss-of-uAUG mutations in EPHB1 and MAP2K6 induce downstream translation. Focusing on 
genetic variants that functionally ablated uORF initiation codons, we analyzed the expression of related tran-
scripts in the original cancers. Wherever primary material was available, the affected transcripts were readily 
detected by semi-quantitative real-time PCR, suggesting that the observed uORF-altering mutations may have 
been translationally active in vivo (Fig. 3A and Supplementary Figure 1). To monitor the translational impact of 
the loss-of-function uORF alterations, TLSs containing either the wild-type (wt) or the disrupted uORF initiation 
site were introduced into a luciferase uORF-reporter system as previously described5 (Fig. 3A, Supplementary 
Table 6). Two mutations, comprising the uAUG to uGUG mutation in EPHB1 and the uAUG to uACG mutation 
in MAP2K6, as well as the uAUG-deleting SNP variant in KDR, induced enhanced translation of the down-
stream coding sequence to various extends (Fig. 3B), while the uAUG-ablating alterations in BLK, JAK2 and the 
SNP in EPHA3 showed no detectable effects on reporter expression. The loss-of-uAUG mutation in EPHB1 was 
associated with a mild enhancement of reporter expression (approximately 30%), whereas the uORF-disrupting 
mutation in MAP2K6 caused a marked induction of translation (approximately 3-fold). This was within the range 
of translational induction observed for other uORF-regulated transcripts5,6. For both, EPHB1 and MAP2K6, wt 
and mutant transcript levels did not differ significantly, excluding the possibility that changes in transcription or 
mRNA stability accounted for the observed variation of protein levels (Fig. 3C).
Thus, our targeted screening approach revealed unprecedented experimental evidence for rare loss-of-uAUG 
mutations in human cancer. In analogy to non-malignant diseases14,15, the genetic ablation of functionally 
active uORFs may contribute to malignant transformation in individual cases by inducing overexpression of a 
related downstream oncoprotein. Depending on the type of cancer, EPHB1 has been linked to tumor-suppressor 
and oncogenic functions by affecting major cellular programs including cell cycle control, apoptosis, regula-
tion of cell-cell contacts, and migration21–23. For MAP2K6, two previous reports suggested a proto-oncogenic 
role of MAP2K6 overexpression in various types of solid cancer, including colon adenocarcinoma24,25, yet, the 
Figure 2. Recovery of genetic information of targeted uAUG regions and identification of uORF-associated 
alterations in human cancers. (A) Heatmap displaying the number of sequencing reads for individual uAUG 
target sites (rows) and individual cancer samples of indicated entities (columns). The threshold was set to ≥10 
sequencing reads (seq. reads) (see also Supplementary Table 2). (B) Summary of sequencing data processing. 
The top pie chart shows the proportion of all individual target sites (404 uAUGs of 308 cancer samples) that 
were covered by ≥10 sequencing reads. The bottom pie charts represent the numbers of potential genetic 
alterations (mutations, single nucleotide polymorphisms (SNPs) and long deletion/repeat regions) in uAUG 
and uKozak target sites that showed ≥10% deviation from the reference base (ref. base)(see also Supplementary 
Tables 3 and 4). Selected candidate mutations were subsequently re-sequenced by Sanger confirming the 
indicated number of uORF-associated alterations.
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mechanism of the tumor-specific elevation of MAP2K6 protein levels was not investigated. As the MAP2K6 
mutation identified in our screen originated from a colon adenocarcinoma sample, we performed additional 
luciferase assays in the colon cancer-derived cell lines Caco2 and HCT116. Similar to the results observed in HeLa 
cells, the loss-of-function uORF mutation proved to be translationally active in colon cancer cells (Fig. 3D). Of 
note, the MAP2K6 uORF mutation was observed in the normal control tissue of the affected patient as well, sug-
gesting a germline transmission of the variant allele that may have encompassed predisposition to tumor develop-
ment. However, no further information on the patient’s family history was available. Very recently, the MAP2K6 
uAUG variant has been observed in an independent whole genome sequencing analysis (SNP rs751306749)20, yet 
the functional role and frequency of this variant remains obscure.
Figure 3. Translational impact of identified loss-of-uORF mutations. (A) Schematic representation showing 
the position and length of uORFs with identified uAUG-associated mutations and polymorphisms (p) in the 
indicated transcripts. Conservation of affected uORF start sites among nine vertebrate species (human, rhesus, 
mouse, rat, cow, dog, elephant, chicken, and zebrafish) is indicated and the quality of uKozak contexts is 
depicted as intermediate (+, one core uKozak base match) or weak (−, no core uKozak base match). Additional 
columns display the detected sequence of the mutant codon, the affected cancer sample and the expression 
of indicated transcripts in affected cancer samples determined by semi-quantitative real-time PCR (see also 
Supplementary Fig. 1). Note that all transcripts contained additional uORFs that were devoid of genetic 
alterations and are not illustrated here (see also Supplementary Table 6 and Supplementary Fig. 2). n.a. - not 
analyzed due to the lack of cancer material. (B,C) Luciferase assays and real-time PCR analysis in HeLa cells 
showing relative luciferase activities and mRNA levels in the presence of indicated TLSs containing wild-type 
(red or orange) or mutant (gray) uORF initiation sites as shown in (A). (D) Luciferase assays demonstrating 
relative luciferase activities in the presence of the wild-type (red) or mutant (gray) uORF initiation codon in 
the TLS of MAP2K6 in two indicated colon cancer-derived cell lines. Error bars represent means ± standard 
error of the mean (s.e.m) of Firefly luciferase signals relative to Renilla luciferase internal control signals from 
duplicate measurements of at least three (b,c) and two (d) independent experiments. Statistical significance was 
determined by the two-tailed, non-parametric Mann-Whitney test and is indicated by *P < 0.05, **P < 0.01 and 
***P < 0.001. Numbers identify the specific cancer sample affected by the uAUG alteration.
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As shown before, the uAUG-deleting SNP variant in KDR resulted in a mild de-repression of downstream 
translation5,6. In a previous report, elevated KDR protein levels were observed in lung cancerous tissue in asso-
ciation with the loss-of-function uORF allele, indicating functionality of the mutant transcript in a tumor envi-
ronment26. Moreover, the uORF-disrupting SNP in KDR has been associated with a trend toward shorter overall 
survival of pancreatic carcinoma patients27; however, the high frequency of the KDR loss-of-uORF allele observed 
in the 1000 genomes analysis does not support a driving role of this SNP (rs7667298) during tumor formation28.
Given the high variability of uORF regulatory functions described in the literature7, the detection of 
non-functional uORF mutants (BLK, JAK2 and EPHA3) was expected. The lack of translational activity may 
be explained by transcript-specific features, including the degree of evolutionary conservation of the uAUG, 
the quality of the uKozak vicinity, or the presence of additional uORFs within the same mRNA (Supplementary 
Fig. 2). Moreover, single nucleotide exchanges in an uAUG always result in a near-cognate non-uAUG codon 
that may occasionally serve as alternative uORF-initiating codon to sustain the inhibitory effect of the original 
uORF on downstream translation29,30. Apart from transcript immanent features, global translational conditions 
and the abundance of translational co-factors may differentially affect individual uORF start sites. In the con-
text of carcinogenesis, recent observations linked uORF-mediated activation of translation to the abundance 
of eukaryotic initiation factors (eIFs) induced by various oncogenic signaling pathways. Both, eIF2A and eIF6 
were shown to specifically direct translation towards complex GC-rich and uORF-bearing mRNAs31. Especially, 
eIF6 is overexpressed in several human cancers including colon cancer32 and contributed to malignant trans-
formation and tumor growth in vivo33,34. Thus, beyond a direct induction of downstream translation through 
loss-of-uAUG mutations, uORFs may serve as sensors of oncogenic signaling, similar to their global role in 
directing nonsense-mediated decay towards uORF-bearing transcripts during stress responses35.
After all, the non-recurrent nature of the uORF-associated genetic alterations detected by our targeted 
sequencing approach precluded extensive experimental investigations on the transforming capacity of individual 
mutations and emphasized the need to increase the number of samples for individual cancer types.
Whole exome sequencing uncovers additional non-recurrent loss-of-uAUG mutations in colon 
cancer. We extended our study to 464 colon adenocarcinoma-derived whole exome sequencing datasets avail-
able through NCI´s Genomic Data Commons portal36 (https://gdc-portal.nci.nih.gov) to further define the fre-
quency of uORF mutations. The genomic positions of the previously identified uORF-mutations in BLK, EPHB1, 
JAK2, and MAP2K6 were covered by ten or more reads in 6, 44, 438, and 141 cancer samples, respectively. None 
of four independent SNP calling tools (SomaticSniper, VarScan2, MuTect2, and MuSE) detected additional cases 
of these variants in the extended colon cancer sample set (data not shown). Given the high coverage for the JAK2 
and MAP2K6 uORF initiation sites, we conclude that the JAK2 and MAP2K6 uORF mutations appeared to be 
non-recurrent in colon cancer.
We also analyzed the exome sequences of tumor samples and corresponding normal controls for somatic 
mutations in all 59818 uORF initiation codons and 47108 associated uORF termination codons, as identified in 
the latest human genome assembly (hg38). The number of uStop codons was lower as compared to the uAUGs, 
because subsequent in-frame uAUGs may share the same termination codon. Furthermore, the analysis did not 
include uORF-related Stop codons located downstream of the respective CDS start site. On average, approxi-
mately 41% of the upstream initiation and termination codons were covered by ten or more reads in both, tumor 
samples and normal controls (Supplementary Figure 3). These data demonstrate that uORF regions are still 
Gene
Chromosome 
coordinates
Reference 
base
SNP 
base
SNP 
freq [%]
uAUG/uKozak 
variation
Number of affected 
cancer samples
Related 
entities
CAMKK2 chr12:121735975 A — 1.4 ATG 2 CA
EPHA3 chr3:89156859 A T 0.2 TTG 1 ALL
KDR chr4:55991731 A G 55.4 GTG 4 MC, ALL, AML, OS
CAMKK2 chr12:121712374 G A n.a. tgcCagATGG 1 AML
MDM2 chr12:69202164 A G 33.7 agtGgaATGG 237 all entities
MUSK chr9:113431103 T C 1.2 caaAgcATGC 2 AML, NHL
NRP2 chr2:206547747 T C 0.6 acaTacATGC 5 MC, CA, AML, NHL
PTK2B chr8:27179964 C T 0.05 tggCagATGA 1 AML
STAT6 chr12:57505073-8 GTGTGT — div. gtgTgtATGTATGT 306/307/265/273/138/146 all entities
TTN chr2:179672033 G A 2.6 tcaGagATGG 2 CA, LX
TYK2 chr19:10490402 T C 16.5 cctTtgATGG 120 all entities
YEATS4 chr12:69753557 G A 0.2 gccTaaATGG 1 OS
Table 1. Summary of verified uORF-associated SNPs. The table shows confirmed annotated SNPs (in bold) in 
uAUGs (top) and uKozak sequences (bottom, uAUG is underlined and core uKozak bases are in capital letters) with 
information of affected genes and cancer samples. Note that the single nucleotide deletion in the uAUG of CAMKK2 
and the 6-bp repeat deletion in the uKozak sequence of STAT6 did not alter the uORF start site or uKozak sequence, 
respectively, as resulting genotypes correspond to the reference base(s). In the case of STAT6, different numbers 
of affected cancer samples were determined for each base in the 6-bp repeat region. freq – frequency; n.a. – not 
annotated; div. – diverse annotations; all entities – ALL, AML, NHL, OS, CA, CX, LA, LX, MC.
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insufficiently covered in current whole exome sequencing datasets, as classical exome sequencing mostly focused 
on protein coding regions and thus neglected substantial parts of the TLSs.
Nevertheless, the four SNP calling tools reported variable numbers of somatic variants, ranging from 100 for 
the MuSE tool to 1940 for MuTect2 tool (Supplementary Figure 3). To maximize specificity, we filtered for SNPs 
that had been identified by all four platforms resulting in the detection of 61 non-recurrent somatic mutations 
(Supplementary Table 9). None of these showed genetic variance among the 1000 genomes dataset. Eight variants 
had been annotated for genetic variability in dbSNP (NCBI) before20. The remaining 53 novel mutations repre-
sented 22 single nucleotide variants (SNVs) functionally deleting a uAUG and 31 SNVs functionally deleting a 
uStop codon, respectively. Again, the non-recurrent nature of these variant alleles precluded the in-depth func-
tional analysis of individual cases.
Conclusions and future prospects. In summary, our systematic PCR-based re-sequencing approach of 
uORF start sites in more than 300 samples derived from seven distinct cancer entities provides initial experi-
mental evidence for rare loss-of-function uORF mutations in human malignancies. Targeting <1% of currently 
annotated uORF initiation codons, we may have missed recurrent uORF variants, as the choice of uORFs was 
biased by previous classifications suggesting a potential uORF-related proto-oncogenic role of the selected genes. 
The absence of recurrent somatic mutations in both, the compilation of distinct cancer entities in the PCR-based 
screen and in the larger cohort of colon adenocarcinomas analyzed by whole exome sequencing, may argue 
against a pivotal role of deregulated uORF-mediated translational control in carcinogenesis. Similarly, we and 
others did not identify recurrent mutations in uORF initiation codons in cancer by exploring publicly available 
databases of genetic variations (ClinVar, COSMIC and TCGA)37. Notwithstanding, our data add loss-of-function 
uORF mutations to the list uORF-mediated mechanisms of translational control, including (I) the adaption of 
protein expression to nutrient supply and growth factor signaling, (II) the activation of mRNA decay through 
uStop-induced ribosome stalling, (III) the regulation of protein isoform expression through uORF-directed alter-
native start site selection, and (IV) the direct interaction of co-factors with the nascent uORF-derived peptide 
(summarized in7). The identification of loss-of-function uORF mutations in human malignancies emphasizes 
the need for comprehensive analyses of uORF regions in the growing number of cancer-derived whole genome 
sequencing datasets. Such efforts will ultimately allow to define the role of uORF-related genetic variability in 
tumorigenesis.
Methods
Patient material. Fresh frozen cancer tissue samples and selected matched normal tissue controls from 
patients with a histologically confirmed diagnosis of cancer were obtained from contributors of the Helios 
Klinikum Berlin-Buch, the Charité Universitaetsmedizin Berlin and the Max-Delbrueck-Center for Molecular 
Medicine Berlin-Buch and analyzed with approval from with the local ethics committee (Ethikkommision, 
Charité, Berlin: EA1/003/13). All experiments were performed in accordance with relevant guidelines and regu-
lations. Informed consent was obtained from all participants and/or their legal guardians.
Genomic tumor DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) after histopathological ver-
ification of a tumor cell content of at least 50% in samples of acute lymphoblastic leukemia (50), acute myeloid 
leukemia (50), non-Hodgkin lymphoma (50), colon (29) and lung (25) adenocarcinoma, mammary carcinoma 
(20), osteosarcoma (35), and colon (26) and lung (23) adenocarcinoma patient-derived xenografts.
Multiplex identifier-tagged PCR deep sequencing approach. Genetic alterations in uORF initiation 
sites were analyzed in three target gene sets consisting of (I) previously defined human tyrosine kinases5, (II) previ-
ously validated proto-oncogenes18 and (III) genes identified manually as being post-transcriptionally overexpressed 
in cancer cell lines from the CellMiner database19. We designed and established 367 customized PCR primer pairs 
(Supplementary Table 7) to amplify 404 uORF initiation sites (including the uKozak context) as mapped by a pre-
vious genome-wide sequence analysis5 using the Pfu Plus! DNA Polymerase (Roboklon). All primers contained a 
5′-extending universal linker sequence (CTCGAGATCT) to facilitate subsequent patient-specific labeling of indi-
vidual amplicons. uAUG-specific PCRs were prepared using the Tecan Evo Pipetting Workstation equipped with a 
384 multichannel pipetting head with disposable tips (Tecan AG, Switzerland).
Based on semi-quantitative gel analysis, similar amounts of uAUG-specific amplicons derived from individual 
cancer samples were pooled and purified using the Invisorb Spin DNA extraction Kit (Stratec). Patient-specific 
Gene
Chromosome 
coordinates
Reference 
base
uAUG/uKozak 
mutation
Number of affected 
cancer samples
Related 
entities
BLK chr8:11351560 G ATT 1 CA
EPHB1 chr3:134514263 A GTG 2 MC, CX
JAK2 chr9:5021969 G ATA 1 NHL
MAP2K6 chr17:67410881 T ACG 1 CA
CHD1L chr1:146731516 G ttgTgtATGA 1 CX
Table 2. Summary of verified uORF-associated novel mutations. The table shows newly identified mutations 
(in bold) in uAUGs (top) and uKozak sequences (bottom, uAUG is underlined and core uKozak bases are in 
capital letters) with information of the affected genes and cancer samples.
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pools of amplicons were labeled in a second round of PCR, using bipartite primers containing the complemen-
tary universal linker sequence and one of 308 previously established multiplex identifier (MID) tag sequences 
(Supplementary Table 8), allowing robust cancer sample discrimination of individual amplicons38.
After another round of agarose-gel-based quantification and spin-column purification, individual MID-tagged 
pools of uAUG-specific amplicons were combined in similar amounts to generate the final sequencing library by 
using the TruSeq gDNA Sample Prep Kit. Deep sequencing was performed on an Illumina® HiSeq2000 sequenc-
ing system with the TruSeq SBS Kit v3 and the PE (paired-end) Cluster Kit v3, producing read lengths of 2 × 101 
nucleotides on average.
Sequencing reads containing cancer-specific MID-tags were aligned to the reference genome (hg19) of the 
UCSC genome browser database39 using bowtie2 v2.0.240. Nucleotide-specific potential base alterations were 
listed for all uAUG and uKozak bases that were covered by 10 or more patient-specific sequencing reads and 
showed a minimal deviation from the reference genome in more than 10% of reads. Of the resulting potential 
uAUG alterations, those with a low probability of representing a true mutation as indicated by variable base sub-
stitutions (e. g. seven reads for the reference base A, and one read each for C, G and T) were excluded manually. 
For all remaining candidate uAUG alterations, uAUG-specific amplicons were regenerated from primary cancer 
DNA and re-sequenced using the Sanger sequencing services of Eurofins Genomics, Germany.
Semi-quantitative real-time PCR analysis. Total RNA was extracted from cancer samples (CA5, CA9, 
CA13, CA15, ALL4, ALL11, ALL16, LA2, LX2, AML3, AML6, NHL29, NHL46, and OS10) using the GeneMATRIX 
Universal RNA purification Kit (Roboklon). DNAse (Roche)-digested RNA extracts were reverse-transcribed 
using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). Semi-quantitative detection of dis-
tinct mRNA levels and HPRT as an internal control was performed with the Power SYBR Green PCR Master Mix 
(Applied Biosystems) and customized real-time PCR primers (BLK-RT for: CACTCCCAAGGCTGATTGAC, 
BLK-RT rev: GCCTCAGACACCAGGATGTT; EPHA3-RT for: AGACAGTTTGCTGCGGTCAG; EPHA3-RT 
rev: GGATGTTCAGGTTCTTGCCA; HPRT-RT for: AGTCTGGCTTATATCCAACACTTCG, HPRT-RT 
rev: GACTTTGCTTTCCTTGGTCAGG; JAK2-RT for: GGGTTAACCAAAGTCTTGCCA, JAK2-RT 
rev: GAGGCCACAGAAAACTTGCTC; KDR-RT for: AGTTGGTGGAACATTTGGGA, KDR-RT rev: 
TCCAGAATCCTCTTCCATGC; MAP2K6-RT for: GCCTATAATGGAACTGGGACG, MAP2K6-RT rev: 
GGCTATTTACTGTGGCTCGGA).
Cell lines. Caco2 (ATCC), HCT116 (ATCC), HeLa (DSMZ) and HEK293 (DSMZ) cell lines were incubated at 
37 °C in a humidified 5% CO2 incubator. Cells were kept in DMEM (Life Technologies) supplemented with 10% 
fetal bovine serum (PAA), 1% HEPES (PAA) and 5% penicillin/streptomycin (PAA).
Generation of constructs for luciferase reporter assays. TLSs containing wild-type (wt) or mutant 
uORF start sites were synthesized (GeneArt, ThermoFisher Scientific) or generated by PCR amplification and sub-
sequent mutagenesis (Supplementary Table 6). TLS inserts also contained the endogenous transcript-specific CDS 
start sites, including the core Kozak base + 4. PCR amplification of TLSs was performed using the Pfu Plus! DNA 
Polymerase (Roboklon) on genomic DNA derived from the HEK293 cell line for EPHA3, EPHB1 and MAP2K6 and 
on HEK-derived cDNA for BLK together with customized PCR primers harboring overhangs for enzymatic restric-
tion (in capital letters): BLK for: ACGGCTAGCcacacagatggcacatggca, BLK rev: GTGCCGCGGCCATccttggcaatgcttca; 
EPHA3 for: CACGCTAGCcccgctctgcttcagcgcac, EPHA3 rev: GGACCGCGGCCATgttgctggtgcagagg; EPHB1 
for: TGCCCCGGGgtcagtctggccggctccgt, EPHB1 rev: CCCAGATCTCCATcgccggccgacggccc; MAP2K6 for: 
TTTGCTAGCagttccaagtttggagcttt, MAP2K6 rev: GTTCCGCGGACATtttcccctttcctttg. PCR-amplified or synthe-
sized TLSs excised from purchased vectors were purified using the Invisorb Spin DNA extraction Kit (Stratec) and 
cloned via flanking restriction sites (BglII–AGATCT, NheI–GCTAGC, SacII–CCGCGG, SmaI–CCCGGG) into a 
previously generated, custom-made Firefly luciferase reporter system5 using T4 DNA ligase (New England Biolabs). 
Site directed mutagenesis of uORFs was performed using the Pfu Plus! DNA Polymerase (Roboklon) and customized 
PCR primers (BLK-mut for: gtggcgttccgctccTTGactgtcgcgcggccg, BLK-mut rev: cggccgcgcgacagtCAAggagcggaacgc-
cac; EPHA3-mut for: tcagtggcatgcttcTTGgagatatgctcctct, EPHA3-mut rev: agaggagcatatctcCAAgaagcatgccactga; 
EPHB1-mut for: aacacacacacacacGTGcacacccacacccac, EPHB1-mut rev: gtgggtgtgggtgtgCACgtgtgtgtgtgtgtt; 
MAP2K6-mut for: cagccctggcccatcACGtagctgcagcacagc, MAP2K6-mut rev: gctgtgctgcagctaCGTgatgggccagggctg).
Luciferase reporter assays. Firefly (custom-made Firefly luciferase vectors with inserted TLSs) 
and Renilla (pRL-CMV vector, Promega) luciferase activities and mRNA levels were measured in lucif-
erase reporter assays and real-time PCR analysis (Firefly for: ATCCATCTTGCTCCAACACC, Firefly 
rev: TCGCGGTTGTTACTTGACTG; Renilla for: GGAATTATAATGCTTATCTACGTGC, Renilla rev: 
CTTGCGAAAAATGAAGACCTTTTAC) as described previously5. Briefly, HeLa, HEK, Caco and HCT116 cells 
were seeded and cultured under standard conditions. After 6 h, cells were transfected with 1 μg/12-well of the 
TLS-Firefly luciferase reporter construct and 30 ng of Renilla luciferase reporter construct using Metafectene 
transfection reagent (Biontex). 42 h later, Firefly and Renilla luciferase activities and mRNA levels were deter-
mined. For each construct, Firefly luciferase signals were normalized to Renilla luciferase internal control signals.
Determinating genomic coordinates of uORFs in hg38. A custom Python script was used to retrieve 
uORF coordinates (available at https://bitbucket.org/TabeaK/uorf-finder). The script uses the RefSeq transcript 
annotation file downloaded from the UCSC Genome Browser to get the chromosome coordinates of all genes. 
For our analysis the RefSeq transcripts of the hg38 human genome assembly were used (UCSC table “refGene”, 
66656 transcripts on 2016-11-17). The script excludes transcripts that do not have any annotated CDS. It then 
extracts the TLS sequence, excluding all intronic regions that might intersect the TLS, and searches for uAUG and 
www.nature.com/scientificreports/
9SCientifiC REPORTS |  (2018) 8:2395  | DOI:10.1038/s41598-018-19201-8
uStop codons (TAA, TAG, TGA). For each uAUG the script identifies the closest in-frame uStop and reports the 
uORFs chromosome coordinates in a BED file.
Whole exome sequencing analysis. On November 3rd 2016, we filtered the gdc sequencing data portal 
(https://portal.gdc.cancer.gov/) for whole exome sequencing datasets derived from colon adenocarcinoma sam-
ples. Variant allele frequencies were available for 492 sample pairs originating from 433 individual cancers and 
normal tissue controls, respectively. Four different SNP calling tools (SomaticSniper at http://gmt.genome.wustl.
edu/packages/somatic-sniper/, VarScan2 at http://dkoboldt.github.io/varscan/index.html, MuTect2 at https://
software.broadinstitute.org/gatk/gatkdocs/org_broadinstitute_gatk_tools_walkers_cancer_m2_MuTect2.php, 
MuSE at http://bioinformatics.mdanderson.org/main/MuSE) were used in the ‘matched mode´, comparing 
tumor and normal datasets. All vcf files were subsetted to the genomic positions of all uAUG and uStop positions 
and analyzed for SNPs that were shared between the different SNP callers.
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